MX2022012310A - Metodos para tratar la esclerosis multiple recidivante con un inhibidor de tirosina quinasa de bruton. - Google Patents
Metodos para tratar la esclerosis multiple recidivante con un inhibidor de tirosina quinasa de bruton.Info
- Publication number
- MX2022012310A MX2022012310A MX2022012310A MX2022012310A MX2022012310A MX 2022012310 A MX2022012310 A MX 2022012310A MX 2022012310 A MX2022012310 A MX 2022012310A MX 2022012310 A MX2022012310 A MX 2022012310A MX 2022012310 A MX2022012310 A MX 2022012310A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- multiple sclerosis
- bruton
- inhibitor
- tyrosine kinase
- Prior art date
Links
- 201000006417 multiple sclerosis Diseases 0.000 title abstract 2
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 title 1
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 abstract 1
- 229950009618 fenebrutinib Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
En la presente se proporcionan métodos para tratar la esclerosis múltiple recidivante (RMS) en un sujeto que lo necesita, al administrar al sujeto alrededor de 200 mg de fenebrutinib dos veces por día, o una cantidad equivalente de una sal farmacéuticamente aceptable de este.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063005095P | 2020-04-03 | 2020-04-03 | |
| US202063051767P | 2020-07-14 | 2020-07-14 | |
| PCT/US2021/025301 WO2021202825A1 (en) | 2020-04-03 | 2021-04-01 | Methods of treating relapsing multiple sclerosis using an inhibitor of bruton's tyrosine kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022012310A true MX2022012310A (es) | 2022-10-27 |
Family
ID=75625678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022012310A MX2022012310A (es) | 2020-04-03 | 2021-04-01 | Metodos para tratar la esclerosis multiple recidivante con un inhibidor de tirosina quinasa de bruton. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230149395A1 (es) |
| EP (1) | EP4125906A1 (es) |
| JP (1) | JP2023520469A (es) |
| KR (1) | KR20220163986A (es) |
| CN (1) | CN115916205A (es) |
| AU (1) | AU2021249129A1 (es) |
| BR (1) | BR112022019846A2 (es) |
| CA (1) | CA3177390A1 (es) |
| CL (1) | CL2022002699A1 (es) |
| IL (1) | IL296990A (es) |
| MX (1) | MX2022012310A (es) |
| TW (1) | TW202203925A (es) |
| WO (1) | WO2021202825A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230171449A (ko) | 2021-05-14 | 2023-12-20 | 록쏘 온콜로지, 인코포레이티드 | 브루톤 티로신 키나제 억제제의 공결정질 형태 |
| CN114028393B (zh) * | 2021-11-07 | 2023-07-18 | 天津医科大学 | 阿帕替尼在制备治疗多发性硬化症药物的用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| EP4049660A1 (en) | 2016-02-29 | 2022-08-31 | F. Hoffmann-La Roche AG | Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase |
-
2021
- 2021-04-01 BR BR112022019846A patent/BR112022019846A2/pt unknown
- 2021-04-01 CN CN202180035499.8A patent/CN115916205A/zh active Pending
- 2021-04-01 EP EP21720649.9A patent/EP4125906A1/en active Pending
- 2021-04-01 TW TW110112266A patent/TW202203925A/zh unknown
- 2021-04-01 WO PCT/US2021/025301 patent/WO2021202825A1/en active Application Filing
- 2021-04-01 AU AU2021249129A patent/AU2021249129A1/en active Pending
- 2021-04-01 CA CA3177390A patent/CA3177390A1/en active Pending
- 2021-04-01 US US17/995,259 patent/US20230149395A1/en active Pending
- 2021-04-01 JP JP2022559934A patent/JP2023520469A/ja active Pending
- 2021-04-01 KR KR1020227037384A patent/KR20220163986A/ko unknown
- 2021-04-01 IL IL296990A patent/IL296990A/en unknown
- 2021-04-01 MX MX2022012310A patent/MX2022012310A/es unknown
-
2022
- 2022-09-30 CL CL2022002699A patent/CL2022002699A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220163986A (ko) | 2022-12-12 |
| CA3177390A1 (en) | 2021-10-07 |
| US20230149395A1 (en) | 2023-05-18 |
| AU2021249129A1 (en) | 2022-10-20 |
| TW202203925A (zh) | 2022-02-01 |
| WO2021202825A1 (en) | 2021-10-07 |
| IL296990A (en) | 2022-12-01 |
| CL2022002699A1 (es) | 2023-03-31 |
| JP2023520469A (ja) | 2023-05-17 |
| CN115916205A (zh) | 2023-04-04 |
| EP4125906A1 (en) | 2023-02-08 |
| BR112022019846A2 (pt) | 2022-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022006865A (es) | Tetrahidrofuranos sustituidos como moduladores de canales de sodio. | |
| EP1933833B8 (en) | Therapy for the treatment of overactive bladder | |
| RS51961B (en) | APPLICATION OF FLIBANSERINE FOR TREATMENT OF SEXUAL DESIRE DISORDERS IN PREMENOPAUSE | |
| MX2022012310A (es) | Metodos para tratar la esclerosis multiple recidivante con un inhibidor de tirosina quinasa de bruton. | |
| RS50876B (sr) | Upotreba flibanserina u lečenju seksualnih poremećaja | |
| MX2023000812A (es) | Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton. | |
| MX2022013647A (es) | Imidazopiridazinas como moduladores de il-17. | |
| AU2018282104A1 (en) | Use of vibegron to treat overactive bladder | |
| MX2022000430A (es) | Administracion de agonista de sting e inhibidores de puntos de control. | |
| MX2023000187A (es) | Dosificacion de vibegron para el tratamiento de vejiga sobreactiva. | |
| MX2022013650A (es) | Imidazopirimidinas como moduladores de il-17. | |
| MX2021013942A (es) | Metodos de tratamiento de la urticaria cronica espontanea utilizando un inhibidor de la tirosina quinasa de bruton. | |
| ATE311928T1 (de) | (-)-pseudoephedrin als sympathomimetisches arzneimittel | |
| MX2022010513A (es) | Metodos para tratar esclerosis multiple progresiva primaria usando un inhibidor de tirosina quinasa de bruton. | |
| EE200300129A (et) | Distamütsiini alfa-halogenoakrüloüülderivaadi kasutamine | |
| TW200503666A (en) | Treatment of type 1 diabetes with pde5 inhibitors | |
| CL2023000296A1 (es) | Uso de dexpramipexol para el tratamiento del asma moderado a grave | |
| HUP9903679A2 (hu) | Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására | |
| MX2022016341A (es) | Formas farmaceuticas de maleato de acalabrutinib. | |
| WO2021239928A3 (en) | Treatment of cardiometabolic disease with inhibitors of type i interferon signalling | |
| MX2021009488A (es) | Uso de vibegron para tratar la vejiga hiperactiva. | |
| PT1259229E (pt) | Utilizacao de benzotieno-[2,3-d]-pirimidinas com uma accao inibidora da pde v no tratamento do disfuncao erectil | |
| IL151878A0 (en) | Pharmaceutical compositions containing t3 | |
| MX2022007304A (es) | Uso de lemborexant para tratamiento del insomnio. | |
| MX2023008904A (es) | Regimen de dosificacion para el tratamiento del eczema cronico de manos. |